Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 31:9:30-6.
doi: 10.2174/1874306401509010030. eCollection 2015.

Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis

Montserrat Vendrell  1 , Gerard Muñoz  2 , Javier de Gracia  3
Affiliations

Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis

Montserrat Vendrell et al. Open Respir Med J. .

Abstract

There is currently less experience with inhaled tobramycin in non-cystic fibrosis bronchiectasis than in cystic fibrosis (CF). Intravenous formulation and solution for inhalation (TSI) have been studied in non-CF bronchiectasis patients with chronic P. aeruginosa bronchial infection. An improvement in clinical parameters and a reduction in bacterial density have been shown with both inhaled solutions in these patients. However, further trials are needed to determine the most effective dose and administration protocol in these patients. Based on the current evidence, recommendations cannot be made regarding the use of TSI to treat exacerbations. Although no systemic toxicity has been reported in studies specifically investigating this treatment, patients with known kidney disease or ear disorders should be treated with caution. Adverse respiratory effects are reported to be more common in non-CF patients than in CF patients, who tend to be non-smokers and younger. Research is being conducted into the possibility of combining tobramycin with other antibiotics to increase its antibacterial activity. In this review we will present and discuss the published evidence regarding the use of inhaled tobramycin in non-CF bronchiectasis.

Keywords: Bronchiectasis; inhaled; tobramycin.

PubMed Disclaimer

References

    1. Olsen AM. Streptomycin aerosol in the treatment of chronic bronchiectasis; preliminary report. Proc Staff Meet Mayo Clin. 1946;21:53. - PubMed
    1. Wall MA, Terry AB, Eisenberg J, McNamara M, Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet. 1983;1:1325. - PubMed
    1. Carswell F, Ward C, Cook DA, Speller DCE. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis. Br J Dis Chest. 1987;81:356–60. - PubMed
    1. MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989;7:42–48. - PubMed
    1. Ramsey BW, Pepe MS, Quan JM , et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23–30. - PubMed

LinkOut - more resources